Adicet Bio, Inc. (ACET) - 2025 Annual Report Summary
Business Context and Reporting Period
This summary covers the fiscal year ended December 31, 2025, for Adicet Bio, Inc., a clinical-stage biotechnology company developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company operates as a single reportable segment. In December 2025, the company effected a 1-for-16 reverse stock split. As of December 31, 2025, the company had 102 full-time employees and maintains operations in Boston, Massachusetts, and Redwood City, California, with research activities in China.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(116.8) million | $(117.1) million |
| Operating Expenses | $122.1 million | $127.6 million |
| Research & Development (R&D) | $99.1 million | $99.3 million |
| General & Administrative (G&A) | $23.0 million | $28.3 million |
| Cash, Cash Equivalents & Short-Term Investments | $158.5 million | $176.3 million |
| Accumulated Deficit | $(614.7) million | $(497.9) million |
| Net Cash Used in Operating Activities | $(95.2) million | $(92.4) million |
Note: The filing text does not provide specific gross margin or operating margin percentages as the company has no product revenue.
Material Changes vs. Prior Period
- Expense Reduction: Total operating expenses decreased by 4% ($5.5 million) year-over-year. G&A expenses declined 19% primarily due to reduced stock-based compensation ($3.6 million decrease) and lower rent/office expenses. R&D expenses remained relatively flat, with a decrease in payroll offset by a $5.6 million increase in contracted research costs (CROs) for autoimmune studies.
- Capital Raising: In October 2025, the company completed an underwritten registered direct offering, raising approximately $74.8 million in net proceeds. This followed a January 2024 offering that raised $91.7 million.
- Interest Income: Interest income decreased 46% to $5.8 million, attributed to lower interest rates and lower cash balances compared to the prior year.
- Debt: The company terminated its loan agreement with Banc of California in late 2024, repaying all outstanding indebtedness. As of year-end, there were no term loans outstanding, though $2.9 million of restricted cash remains held as collateral for ancillary services.
Guidance, Outlook, and Management Commentary
Pipeline Prioritization: Management has strategically prioritized resources toward two main candidates:
- prula-cel (ADI-001): An allogeneic gamma delta T cell therapy for autoimmune diseases. In October 2025, the company announced positive preliminary results from seven patients with Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE). The FDA granted Fast Track Designation for LN, SLE, and Systemic Sclerosis (SSc). The company plans to meet with the FDA in Q2 2026 regarding pivotal trial design and expects to initiate a pivotal study in H2 2026.
- ADI-212: A gene-edited candidate targeting prostate-specific membrane antigen (PSMA) for metastatic castration-resistant prostate cancer (mCRPC). The company expects to submit a regulatory filing in Q3 2026 and initiate enrollment in Q4 2026.
Discontinued Programs: Development of ADI-270 (renal cell carcinoma) was discontinued in July 2025 to optimize resource allocation.
Liquidity Outlook: Management believes that as of December 31, 2025, cash and short-term investments of $158.5 million are sufficient to fund operations into the second half of 2027. However, the company expects to incur significant losses for the foreseeable future and will require additional financing to complete development and commercialization.
Risks and Contingencies:
- Regulatory Uncertainty: The novel nature of allogeneic gamma delta T cell therapies creates uncertainty regarding regulatory pathways and approval timelines.
- China Operations: The company faces regulatory risks related to the Foreign Investment Law and data transfer restrictions in China, where it conducts R&D.
- Internal Controls: The company previously identified a material weakness in internal controls over financial reporting related to cash disbursements in Q4 2024, which management states has been remediated as of the date of this report.
- Collaboration Dependence: The company relies on collaborations with Regeneron, CRISPR, and City of Hope for technology and funding.
Key Facts for Investor Verification
- Cash Runway: Verify the accuracy of the management's projection that $158.5 million in liquidity will sustain operations into the second half of 2027, given the high burn rate of approximately $95 million annually.
- prula-cel Clinical Data: Review the full clinical data release regarding the October 2025 preliminary results for LN and SLE patients to assess the durability of response and safety profile.
- Regulatory Milestones: Monitor the Q2 2026 FDA meeting for prula-cel to confirm the agreed-upon design for the potential pivotal trial.
- China Regulatory Status: Confirm the current status of the company's operations in Shanghai following the acquisition of the VIE (Shanghai Adicet) and ensure compliance with evolving Chinese data and foreign investment laws.
- Stock-Based Compensation: Note the significant volatility in stock-based compensation expenses ($14.3 million in 2025 vs. $22.2 million in 2024) and its impact on future expense projections.